NOVAVAX INC

Novavax reported second quarter 2026 total revenue of $57 million, a 76% decrease year-over-year, and a net loss of $53 million, compared to net income of $107 million in the prior year, which benefited from significant milestones. Despite the quarterly loss, the company raised its full-year 2026 revenue framework to between $235 million and $275 million and improved its combined R&D and SG&A expense guidance. Strategic progress with Sanofi includes potential milestones of $125 million for Phase 3 trial initiation and $75 million for manufacturing technology transfer.

Novavax reported a significant decline in its second-quarter 2026 financial results, with revenue dropping 76% year-over-year to $56.7 million and a net loss of $53.4 million, compared to a net income in the prior year. For the first six months of 2026, the company recorded a net loss of $62.9 million on revenue of $196.2 million, down 78% from the previous year. The company continues to navigate strategic partnerships, including the Sanofi collaboration and the Gavi settlement, while facing challenges with its Australia APA.

Novavax reported first quarter 2026 total revenue of $140 million, a 79% decrease year-over-year, primarily due to non-cash sales in the prior year, and a net loss of $9 million. Operationally, the company made significant progress by signing a Matrix-M license agreement with Pfizer, which included a $30 million upfront payment, and securing four additional Material Transfer Agreements (MTAs) with pharmaceutical companies. Novavax also prioritized its C. difficile vaccine candidate for potential clinic entry as early as 2027 and reiterated its full year 2026 financial guidance.

Novavax reported a net loss of $9.5 million for Q1 2026, a significant decline from a net income of $518.6 million in Q1 2025. Total revenue decreased by 79% to $139.5 million, primarily due to a sharp drop in product sales. The company also entered into a License and Option Agreement with Pfizer for its Matrix-M™ adjuvant, including a $30 million upfront payment and potential milestones up to $500 million. Additionally, Novavax secured a new senior secured term loan facility of up to $330 million, with $50 million funded at closing.

Novavax, Inc. (NVAX) reported $1.1 billion in total revenue for 2025, alongside a 42% reduction in Non-GAAP Combined R&D and SG&A expenses compared to 2024. The company ended 2025 with an $857 million cash position and a 40% reduction in total liabilities. For its 2026 Annual Meeting, Novavax proposes to increase shares available under its 2015 Stock Incentive Plan by 9.4 million and its 2013 Employee Stock Purchase Plan by 1 million shares, totaling 10.4 million new shares. The company also highlighted progress on its corporate strategy, including milestones with Sanofi and advancing its R&D pipeline.